Leerink Partners Reiterates “Market Perform” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report)‘s stock had its “market perform” rating restated by Leerink Partners in a report released on Tuesday, MarketBeat.com reports. They presently have a $1,077.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $1,175.00. Leerink Partners’ target price suggests a potential upside of 4.45% […]
26 Sep 04:01 · The Cerbat Gem